Navigation Links
Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
Date:5/7/2009

MACCLESFIELD, England, May 7 /PRNewswire-FirstCall/ -- Cyprotex today (7th May 2009) launches Cloe(R) Gateway, a new secure web portal for access to drug discovery services. The initial offering via Cloe(R) Gateway is a new enhanced version of our proprietary predictive software, Cloe(R) PK, which predicts whole body pharmacokinetics from simple in vitro ADME and physicochemical properties.

Commenting on the launch, Dr Anthony D. Baxter, Cyprotex's Chief Executive Officer, said:

"I am delighted to announce the launch of our new and novel web portal Cloe(R) Gateway and its first product, an improved version of Cloe(R) PK. Cloe(R) PK, as a server based product, has been used by many of our customers for prediction of pharmacokinetic properties from early ADME data and found it to be very useful in decision making for candidate selection. Cyprotex have invested considerable time and effort improving the Cloe(R) PK model and we are proud to launch version 2.1 as an online service available via Cloe(R) Gateway. This will enable many more of our customers to utilise this excellent product on a simple pay-per-use model. The cost effectiveness of this approach will allow access of such predictive technologies to new audiences of scientists such as bench medicinal chemists. This approach to selling software solutions is new to the ADME / pharmacokinetic world and we anticipate it will grow to replace competitor products still being sold on the outdated server / license model.

The pharmaceutical industry has amassed a huge quantity of ADME data over the past few years and the availability of an online version of Cloe(R) PK though Cloe(R) Gateway will enable those companies to realise tremendous real added value from that data in the form of pharmacokinetic performance characteristics to enable faster, cheaper and better designed drugs to be developed.

I look forward to announcing further new products to be sold through Cloe(R) Gateway such as a human intestinal absorption model and a product to enable customers to access our largest selling product Cloe(R) Screen in the near future."

    For further information:
    Cyprotex PLC
    Helen Gill PhD, Product Development Manager
    Tel: +44(0)1625-505-100
    h.gill@cyprotex.com
   http://www.cyprotex.com


'/>"/>
SOURCE Cyprotex Discovery Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cyprotex Purchases Applied Biosystems Sciex QTRAP(R) 5500 LC-MS/MS
2. Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
3. Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tephas Proprietary Biomaterial
4. Elsevier Launches Ten New eBook Specialty Collections on MD Consult
5. Histogen Aesthetics Launches ReGenica Rejuvenation System
6. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
7. GenVault Corporation Launches its Latest Centralized and Standardized Software Solution for Biobanking and Biological Sample Management, GenConnect 3.2
8. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
9. Cell Biosciences Launches Next-Generation Protein Characterization System
10. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension ... are higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... bottom of the cuvette holder. , FireflySci has developed several Agilent flow cell ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):